An Open Label, Observational, Prospective, Non-Comparative, Multicentre Study to Evaluate Asthma Control and Device Usability of Salmeterol/Fluticasone Propionate FDC Administered Through Synchrobreathe in Patients with Persistent Asthma - EVOLVE Study

Cipla Ltd0 个研究点目标入组 490 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.A voluntarily given, written signed dated informed data sharing consent from patients and/or legally acceptable representative
•2.Patients of either gender of age 12 years and above
•3.Subjects with documented diagnosis of asthma who are treatment naÃ¯ve or uncontrolled due to poor inhaler technique
•4.Able and willing to comply with all study requirements
•5.Patients suitable for study as per Investigator and eligible to start treatment with Salmeterol/Fluticasone FDC administered through Synchrobreathe

•1.Hypersensitivity to study drug and/or its components
•2.Acute episode of asthma where intensive measures were used or primary treatment of status asthmaticus
•3.Patients experienced with the use of Synchrobreathe device

发起方